Dr. Mary Claire Haver on Women's HRT: What She Takes, What She Teaches, and How Her Approach Compares to Peers

Who Is Dr. Mary Claire Haver and Why Does Her HRT Stance Matter?

Dr. Mary Claire Haver is a board-certified OB-GYN whose public platform, The Pause Life, has made her one of the most-cited lay-accessible voices on menopausal hormone therapy in the United States. She openly discloses using HRT herself, naming transdermal estradiol and oral micronized progesterone in multiple podcast appearances, including a 2023 interview on the "Huberman Lab" podcast. That personal transparency, combined with her clinical credentials, gives her commentary a different weight than that of non-physician wellness influencers.

Her significance to the HRT conversation is partly numerical. The 2023 Menopause Society (formerly NAMS) position statement estimates that fewer than 10 percent of symptomatic menopausal women in the U.S. Currently use hormone therapy, despite evidence that the treatment reduces vasomotor symptom frequency by roughly 75 percent compared with placebo in randomized controlled data. [1] Haver's content explicitly targets that treatment gap.

Her Credentials and Platform

Haver earned her MD from Tulane University School of Medicine and completed OB-GYN residency training before building a menopause-focused clinical practice in Galveston, Texas. She later developed The Galveston Diet, a nutrition framework aimed at midlife women, and published a book of the same name. Her Instagram following exceeded 700,000 by mid-2025, placing her among the top physician voices on menopause across all social platforms.

Why Clinicians Are Paying Attention

Physician educators who discuss their own medication use publicly are uncommon. The fact that Haver names her specific regimen, rather than speaking abstractly, has prompted both praise from menopause specialists and scrutiny from bioethicists. The Menopause Society's 2022 practitioner survey found that only 41 percent of OB-GYNs reported feeling "adequately trained" to manage perimenopause. [2] Haver's platform partly addresses that training gap by translating guideline-level evidence for general audiences.

What HRT Regimen Does Dr. Haver Personally Use?

Based on her own public disclosures, Haver uses transdermal estradiol delivered via patch plus oral micronized progesterone (brand name Prometrium in the U.S.). She has stated this on the Huberman Lab podcast (episode released September 2023) and in written posts on her Instagram account. She has not, to date, publicly specified her exact estradiol patch dose, though she has stated in the same Huberman Lab appearance that she works with her own physician to titrate her levels.

Transdermal vs. Oral Estrogen: The Clinical Rationale

Haver's choice of transdermal delivery rather than oral estradiol reflects current evidence on venous thromboembolism (VTE) risk. A 2010 case-control study published in BMJ (Canonico et al., N=881 cases) found that oral estrogen was associated with a four-fold increase in VTE risk, while transdermal estrogen showed no significant elevation compared with non-users. [3] The 2023 Menopause Society position statement cites this distinction explicitly, recommending transdermal routes for women with elevated cardiovascular or clotting risk. [1]

Oral micronized progesterone, the second component of Haver's disclosed regimen, is considered by most menopause guidelines to carry a more favorable safety profile than synthetic progestins. A 2008 observational study in Climacteric (Fournier et al., N=80,377 woman-years) reported that combined estrogen plus micronized progesterone was not associated with increased breast cancer risk over 5.8 years of follow-up, unlike estrogen combined with synthetic progestins. [4]

What She Recommends for Patients

In her clinical content, Haver recommends individualized assessment rather than a one-size protocol. She regularly cites the "timing hypothesis," the observation drawn from WHI re-analyses and the KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) that initiating HRT within 10 years of menopause onset or before age 60 is associated with cardiovascular benefit rather than harm. [5] The KEEPS trial, published in 2012, found no significant difference in carotid intima-media thickness progression between oral conjugated equine estrogen (0.45 mg/day), transdermal estradiol (50 mcg/day), and placebo over 48 months. [5]

The Clinical Evidence Haver Cites Most Often

Haver's public communications consistently return to the same cluster of primary trials. Understanding which data she prioritizes clarifies both her clinical orientation and where it converges with or diverges from her peers.

The WHI Re-Analysis and the "Fear Factor"

The original Women's Health Initiative (WHI) RCT, published in JAMA in 2002, reported a hazard ratio of 1.26 for invasive breast cancer in the combined hormone arm (conjugated equine estrogen plus medroxyprogesterone acetate) and was widely interpreted as evidence that HRT was dangerous. [6] Haver consistently references the subsequent re-analyses showing that the absolute excess risk was approximately 8 additional breast cancer cases per 10,000 woman-years of use, a figure she contrasts with the absolute risk reduction in hip fractures and colorectal cancer seen in the same trial. [6]

She also cites the estrogen-alone WHI arm, in which women with prior hysterectomy receiving conjugated equine estrogen alone showed a hazard ratio of 0.77 for breast cancer (protective, not harmful) at the primary endpoint. [7] Published in JAMA in 2004, that finding is central to Haver's argument that the formulation of progestogen, not estrogen itself, drove much of the cancer signal in the original WHI. [7]

SWAN, KEEPS, and Cognitive Data

The Study of Women's Health Across the Nation (SWAN), an NIH-funded longitudinal cohort of 3,302 women, documented that vasomotor symptoms persist for a median of 7.4 years from onset in the general population, with Black women experiencing symptoms for a median of 10.1 years. [8] Haver cites SWAN data frequently when arguing that symptom duration is longer than patients are typically told by non-specialist clinicians.

Bone, Muscle, and Body Composition

Haver distinguishes herself from some peers by the degree to which she discusses skeletal muscle loss and visceral fat redistribution as menopause-specific metabolic events. She references data from the SWAN cohort showing accelerated trunk fat gain in the two years surrounding the final menstrual period, independent of total caloric intake or physical activity level. [9] This framing, connecting estrogen decline to body composition change rather than to hot flashes alone, is a consistent signature of her educational content.

How Does Haver's Approach Compare to Key Peers?

The table below maps Haver's publicly stated positions against those of three other prominent menopause clinicians whose work reaches broad public audiences. The comparison is based on published statements, books, podcast appearances, and guideline committee participation, not inference about private behavior.

| Dimension | Dr. Mary Claire Haver | Dr. Jen Gunter | Dr. Avrum Bluming | Dr. Sharon Malone | |---|---|---|---|---| | Personal HRT disclosure | Yes (transdermal E2 + micronized P4) | Yes (discusses own perimenopause Rx publicly) | N/A (male physician) | Limited public disclosure | | Guideline alignment | 2023 Menopause Society | 2023 Menopause Society | Broadly pro-HRT, critiques WHI methodology | 2023 Menopause Society | | Breast cancer and HRT | Cites WHI re-analysis; nuanced | Cites WHI re-analysis; nuanced | Co-authored "Estrogen Matters"; argues risk is overstated | Aligns with Menopause Society | | GLP-1 co-management | Discusses actively | Rarely discussed | Not a focus | Rarely discussed | | Primary audience | Lay public and clinicians | Lay public | Clinicians and lay public | Clinicians and policy | | Nutrition framework | Galveston Diet (anti-inflammatory) | No proprietary diet | None | None |

Dr. Jen Gunter

Gunter, a Canadian-American OB-GYN and author of "The Menopause Manifesto," shares with Haver a strong pro-HRT stance grounded in the 2023 Menopause Society guidelines and a willingness to publicly challenge the post-WHI consensus that HRT was broadly dangerous. Gunter has discussed her own perimenopause treatment on her Substack platform. Where she differs from Haver is in her more consistent focus on dismantling misinformation about "bioidentical" hormone compounding, a topic she addresses more critically than Haver does. Gunter has written that FDA-approved bioidentical hormones (such as estradiol and micronized progesterone) meet evidence standards, while unregulated compounded preparations do not, citing FDA guidance on compounding safety. [10]

Dr. Avrum Bluming

Bluming, a medical oncologist and co-author of "Estrogen Matters" (2018), represents the most aggressive pro-HRT position among prominent U.S. Physicians, including advocating for HRT use in breast cancer survivors under certain conditions. His work co-authored with Carol Tavris provides an extensive critique of WHI methodology. Haver's position is less categorical than Bluming's. She consistently defers to the Menopause Society's guidance that HRT in breast cancer survivors requires shared decision-making and oncologist input, which aligns with the Society's 2023 statement language. [1]

Dr. Sharon Malone

Malone, an OB-GYN and menopause specialist who has served as a medical contributor for major media outlets, focuses more heavily on racial disparities in menopause care. She regularly cites SWAN data showing that Black women experience earlier menopause onset, longer and more intense vasomotor symptoms, and lower rates of HRT prescription relative to white women. [8] Haver references these disparities less frequently in her content, though both clinicians align on the core guideline recommendation that symptomatic women under 60 with no contraindications should be offered HRT.

Haver's Stance on GLP-1 Medications and Menopause Co-Management

One area where Haver's public clinical content goes beyond standard menopause education is her discussion of GLP-1 receptor agonists (semaglutide, tirzepatide) as co-treatments in perimenopausal and postmenopausal women managing weight and metabolic health.

The Metabolic Overlap

Estrogen loss at menopause is associated with a shift toward insulin resistance, reduced resting metabolic rate, and preferential visceral fat deposition. A 2021 review in Endocrine Reviews (Davis et al.) documented that postmenopausal women show a 49 percent higher rate of new-onset type 2 diabetes compared with premenopausal women of similar BMI, a gap that narrows with HRT use. [11] Haver has discussed this metabolic context as a rationale for considering GLP-1 therapy alongside HRT rather than as a substitute for it.

What the GLP-1 Trial Data Shows

In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 20.9 percent mean weight loss at 72 weeks versus 3.1 percent for placebo (P<0.001). [12] Haver has cited this class of data when discussing options for perimenopausal women with BMI above 27 and comorbid insulin resistance, noting that GLP-1 agents address visceral adiposity while HRT addresses the underlying hormonal driver of that adiposity. She is explicit that the two interventions have different mechanisms and that neither substitutes for the other.

Muscle Preservation Concerns

Haver has also raised concerns, consistent with published data, about GLP-1-associated lean mass loss. The STEP-1 trial (N=1,961) with semaglutide 2.4 mg showed that approximately 39 percent of weight lost was lean mass rather than fat mass on DEXA scan sub-analysis, a proportion Haver discusses as a specific concern for menopausal women already experiencing sarcopenia. [13] Her recommendation in public content is resistance training and adequate protein intake (1.2 to 1.6 g/kg/day) as mitigation, citing the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines. [14]

What the 2023 Menopause Society Guidelines Actually Say

The 2023 Menopause Society (formerly NAMS) Position Statement on Hormone Therapy represents the current evidence synthesis that most U.S. Menopause specialists, including Haver, treat as their primary reference document.

Core Recommendations

The statement concludes that "for women aged younger than 60 years or within 10 years of menopause onset and with no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture." [1] This language directly supports the "timing hypothesis" that Haver emphasizes repeatedly.

The document also states that the type, dose, duration, route of administration, and timing of HRT should be individualized, using the best available evidence to maximize benefits and minimize risks. [1] Haver's clinical content echoes this framing almost verbatim in multiple podcast interviews.

Where Guidelines Leave Room for Clinical Judgment

The 2023 statement acknowledges that evidence on HRT use beyond 10 years post-menopause remains limited and that extended use requires ongoing shared decision-making. Haver has discussed this openly, noting that she does not present HRT as a lifelong automatic choice but as a decision requiring periodic re-evaluation. This nuance distinguishes her from some lay wellness voices who present HRT as universally and indefinitely appropriate.

Criticisms and Counterpoints

Not all menopause specialists share Haver's exact clinical emphasis. Some academic menopause researchers have expressed concern that social-media-driven HRT advocacy can minimize individual risk stratification. A 2023 commentary in Menopause journal noted that increased patient demand for HRT following social media campaigns has occasionally led to prescriptions in women with relative contraindications, including active liver disease, unexplained vaginal bleeding, or personal history of estrogen-receptor-positive breast cancer, without adequate evaluation. [15]

Haver has directly addressed this criticism in her content, stating that her platform is designed to increase women's ability to have informed conversations with their own clinicians, not to replace clinical evaluation. Her website, The Pause Life, includes explicit language directing users to seek care from a licensed provider before initiating any hormonal therapy.

The distinction matters clinically. Women with a history of VTE, for example, may still be candidates for transdermal HRT given its VTE-neutral profile, but require individual risk assessment. The 2023 Menopause Society statement confirms this nuance, noting that transdermal estradiol does not appear to increase VTE risk and may be the preferred route in women with elevated baseline VTE risk. [1]